This HTML5 document contains 104 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00839/identifier/chemspider/
n11http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n21http://linked.opendata.cz/resource/drugbank/dosage/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00839/identifier/wikipedia/
n19http://bio2rdf.org/drugbank:
n16http://linked.opendata.cz/resource/drugbank/drug/DB00839/identifier/pharmgkb/
admshttp://www.w3.org/ns/adms#
n13http://linked.opendata.cz/resource/drugbank/drug/DB00839/identifier/pubchem-compound/
n6http://www.rxlist.com/cgi/generic/
n20http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00839/identifier/pubchem-substance/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/resource/drugbank/medicinal-product/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00839/identifier/kegg-drug/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n23http://www.drugs.com/cdi/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00839/identifier/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/resource/drugbank/drug/DB00839/identifier/national-drug-code-directory/
n25http://linked.opendata.cz/resource/atc/
n24http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00839
rdf:type
n3:Drug
n3:description
A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide. [PubChem]
n3:dosage
n21:271B4A42-363D-11E5-9242-09173F13E4C5 n21:271B4A43-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
The average biological half-life of the drug is 7 hours.
n3:indication
For use as an adjunct to diet to lower the blood glucose in patients with non-insulin dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone.
n3:manufacturer
n11:271B4A32-363D-11E5-9242-09173F13E4C5 n11:271B4A33-363D-11E5-9242-09173F13E4C5 n11:271B4A3A-363D-11E5-9242-09173F13E4C5 n11:271B4A3B-363D-11E5-9242-09173F13E4C5 n11:271B4A38-363D-11E5-9242-09173F13E4C5 n11:271B4A39-363D-11E5-9242-09173F13E4C5 n11:271B4A36-363D-11E5-9242-09173F13E4C5 n11:271B4A37-363D-11E5-9242-09173F13E4C5 n11:271B4A34-363D-11E5-9242-09173F13E4C5 n11:271B4A35-363D-11E5-9242-09173F13E4C5 n11:271B4A3C-363D-11E5-9242-09173F13E4C5 n11:271B4A3D-363D-11E5-9242-09173F13E4C5
owl:sameAs
n19:DB00839 n20:DB00839
dcterms:title
Tolazamide
adms:identifier
n8:5302 n9:DB00839 n12:46505642 n13:5503 n14:D00379 n15:0378-0217-01 n16:PA164774902 n17:Tolazamide
n3:mechanismOfAction
Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.
n3:packager
n11:271B4A25-363D-11E5-9242-09173F13E4C5 n11:271B4A26-363D-11E5-9242-09173F13E4C5 n11:271B4A24-363D-11E5-9242-09173F13E4C5 n11:271B4A30-363D-11E5-9242-09173F13E4C5 n11:271B4A31-363D-11E5-9242-09173F13E4C5 n11:271B4A2A-363D-11E5-9242-09173F13E4C5 n11:271B4A2B-363D-11E5-9242-09173F13E4C5 n11:271B4A28-363D-11E5-9242-09173F13E4C5 n11:271B4A29-363D-11E5-9242-09173F13E4C5 n11:271B4A2E-363D-11E5-9242-09173F13E4C5 n11:271B4A2F-363D-11E5-9242-09173F13E4C5 n11:271B4A2C-363D-11E5-9242-09173F13E4C5 n11:271B4A2D-363D-11E5-9242-09173F13E4C5 n11:271B4A27-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Tolazamide is metabolized to five major metabolites ranging in hypoglycemic activity from 0% to 70%. They are excreted principally in the urine.
n3:synonym
4-(P-Tolylsulfonyl)-1,1-hexamethylenesemicarbazide Norglycin N-{[(hexahydro-1H-azepin-1-yl)-amino]carbonyl}-4-methylbenzenesulfonamide 1-(hexahydro-1H-Azepin-1-yl)-3-(P-tolylsulfonyl)urea Tolazamida CCRIS 591 Diabewas Tolazamid U-17835 Tolazamide N-(P-Toluenesulfonyl)-n'-hexamethyleniminourea BRN 1323565 Tolinase EINECS 214-588-3 Tolazamidum 1-(hexahydro-1-Azepinyl)-3-P-tolylsulfonylurea U 17835
n3:toxicity
Overdosage of sulfonylureas can produce hypoglycemia. Severe hypoglycemic reactions with coma, seizure, or other neurological impairment occur infrequently, but constitute medical emergencies requiring immediate hospitalization.
foaf:page
n6:tolinase.htm n23:tolazamide.html
n3:IUPAC-Name
n4:271B4A48-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4A4E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4A4D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4A4A-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4A4B-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4A4C-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4A46-363D-11E5-9242-09173F13E4C5 n4:271B4A5E-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4A47-363D-11E5-9242-09173F13E4C5 n4:271B4A60-363D-11E5-9242-09173F13E4C5 n4:271B4A44-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4A45-363D-11E5-9242-09173F13E4C5 n4:271B4A61-363D-11E5-9242-09173F13E4C5
n24:hasATCCode
n25:A10BB05
n3:H-Bond-Acceptor-Count
n4:271B4A54-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4A55-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4A4F-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4A50-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4A52-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4A51-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4A53-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly and well absorbed from the gastrointestinal tract.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
1156-19-0
n3:containedIn
n10:271B4A3F-363D-11E5-9242-09173F13E4C5 n10:271B4A41-363D-11E5-9242-09173F13E4C5 n10:271B4A3E-363D-11E5-9242-09173F13E4C5 n10:271B4A40-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4A5A-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4A5C-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4A5D-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4A5F-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4A59-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4A58-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4A5B-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4A49-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4A56-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4A57-363D-11E5-9242-09173F13E4C5